
    
      All subjects who participated in the primary vaccination study, where subjects who received
      GSK Biologicals' hepatitis B vaccine and who will consent to participate in this long-term
      follow-up study, approximately 5 to 6 years after the primary vaccination study. The study
      will be conducted in only 3 centres out of the 4 centres in the primary vaccination study.
    
  